Recent systems biological studies of cardiac systems have greatly advanced our understanding of cardiac physiology with a particular focus on the excitation-contraction coupling. With these advancements, there is a growing interest in systems analysis of the cardiac signaling network because its dynamical property is closely associated with cardiac diseases. In this article, we review recent attempts at computational modeling of the cardiac signaling network and provide a system-level perspective on the analysis of the large-scale cardiac signaling network. We discuss why the systems biological approach is useful and what novel insights it can provide for the development of personalized therapeutic strategies for cardiac diseases in the post-genomic era.
Introduction
With the emergence of systems biology, there have been new attempts to unravel the underlying mechanisms of complex diseases from a network-level perspective [1] [2] [3] . Cardiac diseases are representative complex diseases because they manifest various phenotypes caused by multiple pathologies including myocardial infarction, cardiomyopathies and valvular insufficiencies, which eventually lead to heart failure if untreated [4] . The mechanism of heart failure involves the activation of compensatory circuits that might incur an increase of various neurohormonal factors in the blood [5] . The persistent activation of a subsequent signaling pathway by such circulating factors is a key driver of the pathologic cardiac remodeling and helps perpetuate heart failure phenotype [6, 7] . The relevant signaling pathways are differentially activated depending on the stage of heart failure. In the early stage, the betaadrenergic (b-AR) signaling pathway and angiotensin II (AngII) type 1 receptor signaling pathway are activated to compensate for the reduced cardiac function, whereas in an advanced stage, cytokine receptor signaling pathways are activated to induce cardiac remodeling [8, 9] . Therefore, to understand the mechanism of heart failure progression, it is essential to investigate the dynamical features of cardiac signaling pathways.
During the progression of heart failure, hypertrophy, apoptosis and reduced contractility are the typically observed phenotypes in cardiomyocytes. Apoptosis and hypertrophy of cardiomyocytes are regulated by the intracellular signaling pathways. Contractility of cardiomyocytes is associated with the activity of the ion channels, which are also regulated by the signaling pathways. Hence, the cardiac signaling pathways play a central role in regulating the physiologic and pathologic phenotypes of cardiomyocytes.
Numerous experimental studies have been conducted to understand how cardiac signaling pathways are regulated and how they are related to hypertrophy, apoptosis and contractility of cardiomyocytes. Because cardiac signaling network exhibits considerable complexity in its size and connectivity, there may exist a limitation in using conventional biological approaches, which focuses on identifying the specific function of individual molecular components to understand biological processes, to investigate the underlying mechanism of cardiac diseases [10] . For this reason, there is a growing interest in the systems biological approach that can reduce the biological complexity to facilitate an exploration of hidden dynamics and regulatory principles of complex signal transduction systems [10] . This approach involves the construction of a mathematical model and the computer simulation analysis of it. Using a mathematical model, we can represent a complex signaling network as a system of mathematical equations. Computer simulations can be performed on the mathematical model using numerical algorithms to predict the dynamics of all the signaling proteins [10, 11] . By analyzing the simulation results, the dynamical features of the signaling network can be investigated with or without perturbation of the cellular components. When combined with traditional experimental approaches, such a systems biological approach can enhance our understanding of complex signaling networks [12] [13] [14] [15] [16] [17] [18] [19] .
To date, a number of studies on the cardiac signaling pathway have been performed using systems biological approach. These studies can be classified into two groups. The first group focuses on the role of the signaling pathway for the regulation of cardiac contractility, whereas the second group focuses on the dynamics of cardiac signaling pathways only (e.g. hypertrophy and apoptosis). The studies in this group have investigated the effect of the signaling network on the detailed ion channel dynamics occurring in a millisecond time scale. Representative studies have explored the effect of b-AR signaling on calcium channel dynamics [20, 21] and sodium ion regulation [22] , as well as the effect of Ca 2þ/ calmodulin-dependent protein kinase II (CaMKII) signaling on various ion channel dynamics [23, 24] . Yang et al. provided a comprehensive review of this group of studies [25] . In contrast to the first group, the second group of studies have investigated the dynamics of the signaling pathway that take place in a minute-to-hour time scale without considering ion channel dynamics. This review mainly deals with the second group to highlight recent advances in the understanding of cardiac pathologies through a systems biological approach. The major cardiac signaling pathways involved in the hypertrophy and apoptosis of cardiomyocytes are summarized in the first part. Systems biological studies on cardiac signaling pathways are reviewed intensively in the second part. Then, in the third part, we propose an integrated cardiac signaling network that incorporates the hypertrophic and the apoptotic signaling pathways.
Cardiac signaling network
A cardiac signaling network related to the apoptosis of cardiomyocytes Because cardiomyocytes are terminally differentiated cells, they almost never proliferate after birth [26] . Therefore, loss of cardiomyocytes is related to the permanent reduction of the number of functioning units in the myocardium [26] . Recent studies have shown that apoptosis occurs in cardiomyocytes and contributes to the development of heart failure [27, 28] . Patchy loss of cardiomyocytes owing to apoptosis could be a fundamental part of the myocardial process that initiates or aggravates heart failure. Apoptosis of cardiomyocytes is delicately regulated by specific intracellular signaling pathways.
An important signaling pathway related to the apoptosis of cardiomyocytes is the b-AR signaling pathway. Exposure of cardiomyocytes to a b-AR agonist such as norepinephrine (NE) or isoproterenol (ISO) increased the apoptosis of cardiomyocytes and the apoptotic effect was abolished by the b-AR antagonist, propranolol [29] . In addition, inhibition of protein kinase A (PKA) or L-type calcium channel blocked the apoptotic effects of NE, indicating that the apoptotic effect of the b-AR agonist is mediated by the activation of PKA and increased intracellular calcium concentrations.
The subtype of b-AR that induces the apoptosis of cardiomyocytes was found to be b1-AR, not b2-AR, as the b2-AR antagonist increased apoptosis [29] . The opposing effects of b1-AR versus b2-AR on cardiomyocytes apoptosis are owing to the different signaling pathways activated by b1-and b2-AR. Although both b1-and b2-AR couple to Gs (stimulatory G protein) and exert effects via adenylyl cyclase (AC) and cyclic adenosine monophosphate (cAMP), b2-AR also couples to the Gi (inhibitory G protein) [30] . These results were further supported by the experiments using transgenic mice. In mice that overexpress b1-AR in a cardiac selective context, with an increased frequency of apoptotic cardiomyocytes as measured by TUNEL assay, heart failure developed at about 9 months of age [31] . In contrast, mice that overexpress b2-AR do not appear to develop myocardial dysfunction with age [30] . Concisely, b1-AR stimulation is pro-apoptotic, whereas b2-AR stimulation is antiapoptotic.
The downstream of the b-AR signaling pathway adds more complexity to the regulation of the apoptosis. Abe et al. demonstrated that an autoregulatory positive feedback loop constituted by Phosphodiesterase (PDE) 3A and the inducible cAMP early repressor (ICER) is essential for b-AR-induced cardiomyocyte apoptosis [32] while the CaMKII has been suggested by Xiao et al. to be a major molecule mediating apoptosis [33, 34] .
Mitogen-activated protein kinases (MAPKs) are also involved in the apoptosis of cardiomyocytes. The MAPK family has three members in its classical pathway, including extracellular signal-regulated kinases (ERK1/2), c-Jun N-terminal kinases (JNK) and the protein kinase p38. The MAPK signaling cascade is triggered in cardiomyocytes by G protein-coupled receptors (GPCR), receptor tyrosine kinases [e.g. insulin-like growth factor 1 (IGF-1) and fibroblast growth factor (FGF) receptors], receptor serine/threonine kinases [e.g. transforming growth factor-beta (TGF-b)], and cardiotrophin-1 (gp130 receptor); it is also triggered by stress stimuli such as stretch [35] . Activation of MAPK by b-AR involves PKA-mediated phosphorylation of b2-AR, which induces switched coupling of b2-AR from Gs to Gi; this process leads to an increase in ERK activity to consequently deliver anti-apoptotic signals to cardiomyocytes [36, 37] , which may explain the cardioprotective role of b2-AR induced ERK activation [38, 39] . Activation of JNK exerts a pro-apoptotic effect, while the effect of p38 on cell apoptosis remains controversial [38, 40] . More complex regulation is possible because the activity of ERK1/2 and JNK are interregulated by the family of the dual specificity protein phosphatase 2/4/16 although this interrelationship was reported in tumor cells [41] [42] [43] .
The phosphoinositide 3-kinase (PI3K)-Akt signaling pathway has a protective role in the apoptosis of cardiomyocytes. IGF-1 promoted the survival of cultured cardiomyocytes by activation of PI3K-Akt signaling pathway, the effect of which was abrogated by the PI3K inhibitor [44] . The survival effect is mediated by the inhibition of the pro-apoptotic molecule, Bad, by Akt [45] .
To summarize, activation of CaMK, JNK or ICER induces apoptosis of cardiomyocytes, while activation of ERK1/2 and Akt inhibits it. Stimulation of b-AR coordinates the activity of these molecules, resulting in proper regulation of apoptosis ( Figure 1 ).
The cardiac signaling network related to cardiac hypertrophy
Most pathologic stimuli for heart failure induce the phase of cardiac hypertrophy in which individual cardiomyocytes grow in length and width to increase the cardiac pumping function for a short time inducing compensated hypertrophy. However, in the long run, myocardial hypertrophy predisposes individuals to heart failure and sudden death [46, 47] . Cardiac hypertrophy involves various signaling pathways like the apoptosis of cardiomyocytes.
Activation of the G-protein coupled receptors by AngII, endothelin-1 or catecholamines mediates cardiac hypertrophy.
These receptors are coupled to the heterotrimeric G proteins of Gaq/11, activating the enzyme PLCb, which hydrolyzes phosphatidylinositol 4, 5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). DAG functions as an intracellular ligand for protein kinase C (PKC), leading to PKC activation, and production of IP3 leads to the mobilization of internal Ca 2þ [48] , which mediates hypertrophic signaling through the calcineurin (CaN)-Nuclear factor of activated T cells (NFAT) activation or CaMKII-histone deacetylase inactivation [49, 50] . Studies using genetically modified mouse models have confirmed that Gaq/Ga11 coupling is necessary to induce pathologic cardiac hypertrophy [51] [52] [53] [54] [55] [56] . Systems biological approaches to the cardiac signaling network | 421 MAPK signaling also plays an important role in cardiac hypertrophy. The mitogen-activated protein kinase kinase (MEK) 1-ERK1/2 pathway acts as a central regulator in the induction of cardiac hypertrophy by elevating the transcriptional activity of NFAT, indicating cross-talk with the CaN-NFAT circuit. Transgenic mice that express activated MEK1 developed concentric hypertrophy, which is consistent with compensated hypertrophy without signs of lethal cardiomyopathy [57] .
In contrast to MEK1 overexpression, overexpression of the upstream regulator Ras induced pathological ventricular remodeling and premature death [58] . Ras not only activates the MEK1-ERK1/2 pathway, but also activates the JNK branch of the MAPK cascade, PI3K and other intracellular signaling pathways, increasing the overall activity of related signaling pathways [59] .
Meanwhile, p38 and JNK are involved in developing lethal cardiomyopathy without hypertrophic enlargement. Activation of p38 and JNK in cardiomyocytes leads to downregulation of CaN activity by directly antagonizing NFAT nuclear occupancy [60] . Expression of dominant-negative JNK1/JNK2, MEK3, MEK6 or p38a in the heart was found to promote increased cardiac growth [61, 62] .
The CaN-NFAT pathway is considered to be a central prohypertrophic signaling circuit [61] . This pathway is regulated by GPCR and MAPK pathways as described earlier. Increased Ca 2þ levels activate CaN, which dephosphorylates NFAT, enabling it to translocate to the nucleus. The nuclear translocation of NFAT is necessary and sufficient for inducing cardiac hypertrophy [63, 64] .
The PI3K-AKT pathway has been proposed to regulate the physiologic growth of heart. PI3K converts PIP2 to PIP3, which recruits AKT and phosphoinositide-dependent kinase-1 (PDK1) to the plasma membrane. When PDK1 and AKT are brought into close proximity, PDK1 phosphorylates and activates AKT. PI3Ka is a heterodimer that consists of p85 regulatory subunit and p110 catalytic subunit [65] . The expression of constitutively active p110a in the heart produced a form of physiological cardiac hypertrophy, whereas the genetic deletion of p85 resulted in the reduced heart size [66, 67] .
The PI3K-AKT pathway induces hypertrophy through various other signaling molecules. Glycogen synthase kinase3beta (GSK-3b), which is inhibited by AKT-mediated phosphorylation, negatively regulates hypertrophic transcriptional effectors, such as GATA4, beta-catenin, c-Myc and NFAT [68, 69] . GATA4 is a zinc-finger-containing transcription factor that can regulate the hypertrophic gene expression, whereas betacatenin is a cytoplasmic structural protein that can be translocated to the nucleus, inducing pro-hypertrophic gene expression [70] .
Finally, there exist negative regulators of cardiac hypertrophy that can be suggested as candidates for the treatment of heart failure. Atrial natriuretic peptide (ANP), brain natriuretic peptide and nitric oxide activate guanyl cyclases, which in turn generates cyclic guanosine monophosphate, leading to the activation of protein kinase G (PKG) 1. The activation of PKG1 in cultured cardiomyocytes was found to reduce hypertrophic growth and inhibited pathological cardiac hypertrophy [71, 72] . Active PKG1 inhibits the CaN-NFAT, PI3K-Akt and ERK1/2 pathways, resulting in negative regulation of cardiac hypertrophy [71, 73] .
In summary, the CaN-NFAT pathway, PI3K-Akt pathway and ERK1/2 pathway promote cardiac hypertrophy, whereas PKG suppresses the activity of these three pathways (Figure 1 ).
Mathematical models of the cardiac signaling network
In contrast to the numerous mathematical models regarding the cardiac electrophysiology, there have been only a limited number of mathematical models for the signaling pathways of cardiomyocytes. In this part, we will review several recent studies focusing on the nature of biological problems that can be solved through a systems biological approach, novelty of a modeling method and new insights that can be obtained by the systems biological approach [74] [75] [76] [77] [78] .
Investigation into the role of CaN-NFAT signaling pathway in cardiac hypertrophy
The CaN-NFAT signaling pathway has essential roles in cardiomyocytes for many physiological processes including hypertrophy and contractility [79] . The distinguishing feature of NFAT is its regulation by Ca 2þ and CaN. NFAT proteins are phosphorylated and reside in the cytoplasm in resting cells; upon stimulation, they are dephosphorylated by CaN, translocate to the nucleus and become transcriptionally active to regulate hypertrophic genes, thus providing a direct link between intracellular Ca 2þ signaling and gene expression (excitation-transcription coupling) [80] . Cooling et al. used computational models of CaN-NFAT signaling and found that NFAT activity is sensitive to excitation-transcription coupling when calcium signals from both the cardiomyocyte beating and the hypertrophic signal transduction are in the same cellular compartment [77] . The regulator of calcineurin 1 (RCAN1), a protein encoded by one of the target genes of NFAT, binds and inhibits CaN [81, 82] . However, previous studies have shown that RCAN1 facilitates CaN-NFAT signaling under various experimental conditions, and this has led to controversy regarding the functional role of RCAN1 [83] [84] [85] . As RCAN1 is closely associated with cardiac pathophysiology, the question of how RCAN1 coordinates such different cellular functions has drawn increasing attention [85] . Using a computational model, Shin et al. showed that the functional role of RCAN1 changes in a dose-dependent manner and this role change can be explained by a transcriptional negative feedback loop that includes a large NFAT threshold for RCAN1 expression [78] . At low or moderate NFAT activity, RCAN1 expression is low and therefore CaN inhibition is small, inducing hypertrophy. However, when NFAT activity crosses a certain threshold, RCAN1 expression increases and this largely promotes CaN inhibition, attenuating hypertrophy. To further elucidate the mechanism underlying the RCAN1 regulatory system, Shin et al. used a systems biological approach by combining biochemical experimentation with in silico simulations [76] . Mathematical modeling of CaN-NFAT signaling identified an incoherent regulation circuit where the non-phosphorylated RCAN1 binds to CaN and inhibits its activity (negative regulation), whereas the sequentially phosphorylated RCAN1 facilitates CaN-NFAT signaling (positive regulation). This incoherent regulation circuit coordinates the role change of RCAN1 in which the cross-talk signals mediated through ERK and GSK-3b divert the negative regulation by RCAN1 to a positive regulation [76] . The nuclear NFAT level was prominently increased in the cardiomyocytes expressing constitutively active CaN but was exported to the cytosol when the cells were further cotransfected with CFP-RCAN1 S108/112A
, where both ERK and GSK-3b phosphorylation sites were mutated to alanine, which supports the experimental evidence for the model prediction [76] . These studies suggest important implications for therapeutic strategies to regulate cardiac hypertrophy through modulation of CaN-RCAN1 activity.
A large-scale signaling network model for cardiac hypertrophy
To elucidate the underlying mechanism of cardiac hypertrophy, Ryall et al. constructed a large-scale signaling network [75] . Their network consists of 106 nodes and 193 links, and covers 14 signaling pathways regulating the growth of cardiomyocytes. For a large-scale network of this size, it is impossible to build a mathematical model using detailed biochemical mass action or Michaelis-Menten kinetics because a large number of parameters cannot be determined uniquely owing to the limitations of the experimental data. Instead, they developed a new modeling method, normalized-Hill differential equations, and adopted this method for their computational model [86] . This modeling method uses logic-based differential equations to represent activation or inhibition reactions using normalized-Hill functions together with AND/OR gates to compute cross-talk. Using this method, a mathematical model was constructed, which is validated against published experimental data testing the effects of receptor activation on transcriptional factors and myocyte phenotypic outputs.
Topologically, their network model includes eight hubs, which have more than eight neighbors and are enriched with 'bi-fan' network motifs, indicating a high level of cross-talk. From simulations using normalized-Hill differential equations, different patterns of activation between the two hypertrophic agonists can be clearly observed as well as the network species with similar activation patterns. The MAPK pathway is activated by phenylephrine (PE) but not by tumor necrosis factor (TNF)-a, whereas PI3K is activated by both agonists. Similar patterns of activation can be found in small GTPases Rac1, Raf1A, Ras and RhoA as well as in the members of the MAPK pathway MEK1/2, MEK4 and MEK7.
From the sensitivity analysis of the model, they also revealed quantitative relationships in the hypertrophy signaling network that are not apparent from simple observation of the network topology [75] . The most effective intervention for reducing ANP expression is Ras inhibition followed by (in the order of effectiveness at reducing ANP expression) Janus kinase and JNK inhibition even though these three species are included in the same pathway [75] . They also proposed a modular organization of the hypertrophy signaling network using k-means clustering analysis of the sensitivity matrix. The network was composed of 12 modules densely connected to each other. Such frequently observed cross-talk between modules suggests that investigation of the interactions between signaling pathways would be important in understanding cellular regulation of cardiac hypertrophy.
In summary, Ryall et al. presented the first large-scale cardiac hypertrophy network and certain insightful analyses [75] . In addition, this novel method of using normalized-Hill differential equations can be a useful tool to simulate general largescale biological networks.
Investigation of the role of b-AR in signaling in cardiomyocyte apoptosis
In the heart, stimulation of b-AR plays a central role in increasing cardiac contractility and inducing relaxation in response to stress. However, sustained b-AR stimulation can induce the apoptosis of cardiomyocytes [87, 88] ; the resulting reduction of cardiac contractility is related to the pathophysiology of heart failure [29, 88] , suggesting the importance of b-AR signaling in controlling the progression of heart failure. Over the past decade, compelling evidence has demonstrated that coexisting cardiac b-AR subtypes, mainly b1-AR and b2-AR, activate markedly different signaling cascades. b1-AR transduces the 'pro-apoptotic' signal via the cAMP-dependent signaling pathway, whereas b2-AR transduces the 'anti-apoptotic' signal via the Gicoupled signaling pathway [29, 89] . Such distinct roles for b1-AR and b2-AR were further supported by b1-/b2-AR double knockout mice [90] and cardiac-specific overexpression of b1-AR and b2-AR [91] . Under physiological conditions, however, b-AR agonists (e.g. ISO, NE and epinephrine) bind nonspecifically to both types of receptors, which is puzzling because such nonspecific binding should then convey both 'pro-apoptotic' and 'antiapoptotic' signals simultaneously [92] . In addition, b1-AR and b2-AR share some of their downstream signaling pathways, which are interlinked with each other through complicated feedback regulations [79] . Considering the complexity of the b-AR signaling network and the nonspecific binding characteristics of the b-AR agonists, there has been a difficulty in elucidating the role of the b-AR signaling in cardiomyocyte apoptosis using experimental approaches alone.
Using a systems biological approach, Shin et al. unveiled the underlying signaling mechanism, showing how the apoptosis of cardiomyocytes is determined depending on the level of b-AR activation [74] . In this study, the authors found that the cell fate of cardiomyocytes switches from survival to apoptosis with increasing concentration of the b-AR agonist ISO (a nonselective b1/b2-AR agonist). A gradual increment of ISO induced a switching response of Bcl-2 expression level from initial increase followed by decrease below its basal level; this switching response determined the cell fate of the cardiomyocytes. Using mathematical simulations on the b-AR signaling model, they discovered an ERK1/2 and ICER-mediated incoherent feedforward loop is the hidden molecular switch underlying these cell fate switching characteristics [74] . When cardiomyocytes are exposed to low concentrations of b-AR agonist, the ERK1/2 pathway is activated and induces an increase of Bcl-2 expression level, leading to cell survival. However, when the cells are exposed to high concentrations of b-AR agonist, the activity of the ICER pathway is high, and this induces suppression of the Bcl-2 expression level that promotes cell apoptosis. The cell viability was decreased in cardiomyocytes when treated with ERK inhibitors at a low concentration of ISO, but was increased in cells when transfected with ICER small interfering RNA at a high concentration of ISO [74] , as expected from the model prediction. This study provides new insight into the concentration-dependent cell fate determination mechanism mediated by b-AR signaling in cardiomyocytes and suggests a novel therapeutic strategy for heart disease.
An integrated cardiac network for hypertrophy and apoptosis
Although the systems biological approach to a full cardiac signaling network has been increased over the past decades, phenotypes of hypertrophy and apoptosis have been separately addressed. Because both hypertrophy and apoptosis are involved in the progression of heart failure, it is essential to construct an integrated cardiac signaling network encompassing all the signaling components associated with those two phenotypes.
Systems biological approaches to the cardiac signaling network | 423
We have reconstructed a large-scale cardiac signaling network by integrating the hypertrophic network [75] and apoptotic network [74] . The reconstructed network consists of 103 nodes and 204 links (Figure 2 ). This network contains 15 input nodes (i.e. TNF-a, ISO, NE, PE, IGF1, epidermal growth factor, ET1, AngII, neuregulin 1, TGF-b, interleukin 6, FGF, cardiotrophin1, leukemia inhibitory factor and stretch), which are related to the cardiac environment during heart failure, two output nodes (i.e. cell area and apoptosis) and 86 internal nodes. Internal nodes are colored differently according to the previous networks in which the nodes are included. Yellow and pink nodes were included in the hypertrophic and apoptotic network, respectively. The nodes included in both hypertrophic and apoptotic networks are colored blue. Green nodes (i.e. PDE3/4 [93] , epac [94] , foxo [95] , gab1 [96] , PDE5 [97] , Bim [98] , Bad [99] , RGS [100] and SOCS [101] ) are newly added nodes that were not included in both networks but are related with hypertrophy or apoptosis.
In this integrated network, numerous nodes are involved in the regulation of both apoptosis and hypertrophy. Thus, these two phenotypes are not separately regulated. For instance, calcium activates CaMK and PKC simultaneously, inducing both apoptosis and hypertrophy. In contrast, ERK1/2 suppresses apoptosis through inhibition of ICER and Bim, and facilitates hypertrophy through activation of cFos and cJun.
The network contains various regulatory structures (here, '!' denotes 'activation' and '-j' denotes 'inhibition'): a negative feedback structure (e.g. cAMP ! PKA -j cAMP); a positive feedback structure (e.g. cAMP ! PKA ! ICER -j PDE3/4 -j cAMP); a coherent feedforward structure (e.g. PKA ! ICER and PKA ! CREB ! ICER); and an incoherent feedforward structure (e.g. PKA ! PDE3/4 and PKA ! ICER -j PDE3/4). These structures are interconnected with each other inside the network and can produce complicated dynamic features. Furthermore, cross-talk links (e.g. PKA ! Gia, PKC ! Ras, PKC ! PDE3/4 and CaN ! JNK) are frequently observed in the integrated network, adding further complexity to the network. Because it is difficult to investigate the system behavior in this size of network by only looking at the network topology, mathematical modeling and simulation analysis are essential to analyze the dynamical properties of the network.
Conclusion
Systems biology has emerged as an important research field that can complement experimental studies to expound key biological processes at a system level. In particular, the systems approach is essential to investigate the pathophysiology of cardiomyocytes because it is regulated in a nonlinear way on an interwoven molecular interaction network.
Although computational modeling of cardiac electrophysiology has been performed extensively, the mechanistic modeling of a cardiac signaling network has only recently been initiated. Herein, we have reviewed several systems biological approaches for the cardiac signaling network showing that these approaches can provide novel insights into the dynamic regulation of apoptosis and hypertrophy. These approaches have a great potential to be extended to both well-studied signaling pathways (e.g. GPCR signaling and MAPK signaling) and emerging signaling-related research fields (e.g. cardiac stem cells and cardiac remodeling).
In addition, we have presented an integrated cardiac signaling network. Investigating the topology of this network revealed that various signaling pathways are interwoven through crosstalks so that apoptosis and hypertrophy of a cardiomyocyte are regulated in an interdependent manner. Through modeling and simulation analysis of this large-scale network, molecular dynamics related with pathologic phenotypes could be identified from a network perspective.
Further integration of other cardiac models to this network will improve our understanding of biological phenomena in cardiomyocytes. A recent modeling study revealed that the compartmentalization of cAMP influences the dynamical properties of the signaling network in cardiomyocytes [102] . Integration of that innovative model regarding compartmentalization will contribute to the construction of a more realistic network of cardiomyocytes. Integration of electrophysiological models (i.e. models dealing with detailed ion channel dynamics) may open up a new horizon for cardiac systems biology because the contractility, apoptosis and hypertrophy can be investigated simultaneously. However, this integration would be very difficult to achieve because the time scales of signal transduction (i.e. minutes to hours) and that of ion channel dynamics (i.e. millisecond) are fundamentally different [103] . Until recently, several integrated models have been reported; however, only part of the signaling pathway was included in the models [20] [21] [22] [23] [24] . The integration of electrophysiological models with a full cardiac signaling network will require a new method that can handle dynamics with two different time scales.
Analysis of the integrated cardiac signaling network can also be used to investigate personalized therapeutic strategies for heart disease. In recent decades, there has been increased attention on personalized treatment of heart failure. Treatment responses of heart failure have been reported to vary depending on race, sex and genetic profiles [104, 105] . Specifically, women and African Americans respond less well to Angiotensin Converting Enzyme (ACE) inhibitors [106, 107] , whereas heart failure patients with high tissue ACE activity respond well to the drug [108] . Furthermore, significantly different responses to heart failure therapy were observed in the genetic variants of b-ARs, a-ARs and endothelin receptors [109] . Considering that ACE inhibitors, b-ARs, a-ARs and endothelin receptors are related with the signaling pathway, the treatment response may be influenced by individual characteristics at the level of the cardiac signaling pathway.
Recent clinical surveys have shown that biological traits (e.g. age and sex) and comorbidities (e.g. hypertension, diabetes mellitus and coronary artery disease) of patients with heart failure follow a gradually varying pattern that constitutes a heart failure spectrum. In this regard, each patient under heart failure follows a unique disease trajectory depending on the relative contribution of the patient's traits and comorbidities (called disease modifiers) [110, 111] (Figure 3) . However, insights into the mechanisms of the manner in which these modifiers direct the patient's individual trajectory are incomplete. How do the modifiers coordinate to induce pathologic phenotypes? Is there a genetic background that influences the susceptibility of the heart to be changed by the modifiers? As we described earlier, pathologic phenotypes of the heart are closely associated with changed activity of the signaling pathway. Thus, the disease modifiers might have an effect on some signaling molecules (or signaling pathway) that result in the different phenotypic outcomes (i.e. different disease trajectory). In this regard, a systems biological approach for the cardiac signaling network will be essential to investigate the gradually varying phenotypes. Figure 3 . A conceptual diagram of personalized treatment for heart failure based on network-based stratification. Heart failure is not a single disease entity but can be considered as a disease spectrum including various pathologic phenotypes. The heart failure spectrum represents gradually varying phenotypes over the disease. The extreme types of dysfunction can be placed at either end of the spectrum: systolic or diastolic dysfunction; preserved or reduced ejection fraction; concentric or eccentric ventricular remodeling. Patients follow their own disease trajectories, depending on their biological traits and comorbidities, and eventually reach a point inside the disease spectrum. These distinct trajectories result from the differentially regulated signaling pathways that constitute a personalized signaling network. Taking account of the individual differences in the signaling networks, a mathematical model for each patient can be constructed. From simulation of this personalized model, optimal therapeutic strategies can be found. A colour version of this figure is available at BIB online: http://bib.oxfordjournals.org.
Computational models are becoming necessary to complement experimental studies by explaining experimental findings and identifying hidden key mechanisms that underlies the cardiac system. Computational models can also help integrate different aspects of cardiac function into an organized system to lead to an understanding of the dynamical properties of cardiac signaling network in the pathological progression into heart failure. Such interdisciplinary efforts will facilitate elucidation of the molecular mechanisms underlying the pathogenesis of heart failure and lead to an identification of the critical controlling factors, which will become targets for pharmacological intervention in the treatment of cardiac diseases.
Key Points
• The cardiac signaling pathways play a central role in regulating physiologic and pathologic phenotypes of cardiomyocytes.
• Systems biological approaches are essential to enhance understanding of the cardiac signaling network.
• Analysis of an integrated cardiac signaling network can be useful to investigate the mechanism of heart failure and may further suggest personalized therapeutic strategies for heart diseases.
